CS
IMNM icon

Candriam SCA’s Immunome IMNM Stock Holding History

Candriam SCA’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Buy
680,132
+140,250
+26% +$3M 0.06% 240
2026
Q1 		$11.8M Hold
539,882
– – 0.06% 252
2025
Q4 		$11.6M Sell
539,882
-319,645
-37% -$5.61M 0.06% 256
2025
Q3 		$10.1M Buy
859,527
+541,441
+170% +$5.39M 0.05% 276
2025
Q2 		$2.96M Buy
+318,086
New +$2.61M 0.02% 433

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Candriam SCA's IMNM Position: Q2 2026 in Review

Candriam SCA increased its Immunome (IMNM) stake by 26% in Q2 2026, buying an estimated $3M and bringing the position to 680,132 shares worth $14.4M. The position accounts for 0.06% of the portfolio, ranked #240.

Candriam SCA first reported a position in IMNM in Q2 2025 and has held it in 5 quarters since. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Candriam SCA held 680,132 shares of Immunome worth $14.4M as of Q2 2026.
  • Candriam SCA bought 140,250 Immunome shares in Q2 2026, an estimated $3M.
  • Immunome made up 0.06% of Candriam SCA's portfolio in Q2 2026, its #240 holding.
  • Candriam SCA first reported a position in Immunome in Q2 2025 and has held it in 5 quarters since.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.